{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T12:37:29Z","timestamp":1793191049630,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"GSK"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1007\/s12325-017-0626-4","type":"journal-article","created":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:32:46Z","timestamp":1509496366000},"page":"2518-2533","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":81,"title":["Comparative Efficacy of Once-Daily Umeclidinium\/Vilanterol and Tiotropium\/Olodaterol Therapy in Symptomatic Chronic Obstructive Pulmonary Disease: A Randomized Study"],"prefix":"10.1007","volume":"34","author":[{"given":"Gregory J.","family":"Feldman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana R.","family":"Sousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Lipson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Tombs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H.","family":"Riley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadhana","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Naya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Compton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernardino","family":"Alc\u00e1zar Navarrete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,11,1]]},"reference":[{"key":"626_CR1","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","volume":"380","author":"R Lozano","year":"2012","unstructured":"Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095\u2013128.","journal-title":"Lancet"},{"key":"626_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.5588\/ijtld.15.0472","volume":"20","author":"S Ehteshami-Afshar","year":"2016","unstructured":"Ehteshami-Afshar S, FitzGerald JM, Doyle-Waters MM, Sadatsafavi M. The global economic burden of asthma and chronic obstructive pulmonary disease. Int J Tuberc Lung Dis. 2016;20:11\u201323.","journal-title":"Int J Tuberc Lung Dis"},{"key":"626_CR3","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/resp.12660","volume":"21","author":"JL Lopez-Campos","year":"2016","unstructured":"Lopez-Campos JL, Tan W, Soriano JB. Global burden of COPD. Respirology. 2016;21:14\u201323.","journal-title":"Respirology"},{"key":"626_CR4","unstructured":"Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis,management and prevention of chronic obstructive pulmonary disease (2017). \n                    http:\/\/goldcopd.org\/gold-2017-global-strategy-diagnosis-management-prevention-copd\/\n                    \n                  . Accessed Feb 2017."},{"key":"626_CR5","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1124\/pr.111.004580","volume":"64","author":"M Cazzola","year":"2012","unstructured":"Cazzola M, Page CP, Calzetta L, Matera MG. Pharmacology and therapeutics of bronchodilators. Pharmacol Rev. 2012;64:450\u2013504.","journal-title":"Pharmacol Rev"},{"key":"626_CR6","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1378\/chest.125.1.249","volume":"125","author":"DP Tashkin","year":"2004","unstructured":"Tashkin DP, Cooper CB. The role of long-acting bronchodilators in the management of stable COPD. Chest. 2004;125:249\u201359.","journal-title":"Chest"},{"key":"626_CR7","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/1465-9921-14-49","volume":"14","author":"DP Tashkin","year":"2013","unstructured":"Tashkin DP, Ferguson GT. Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease. Respir Res. 2013;14:49.","journal-title":"Respir Res"},{"key":"626_CR8","doi-asserted-by":"publisher","first-page":"719","DOI":"10.2147\/COPD.S102494","volume":"11","author":"G Feldman","year":"2016","unstructured":"Feldman G, Maltais F, Khindri S, Vahdati-Bolouri M, Church A, Fahy WA, et al. A randomized, blinded study to evaluate the efficacy and safety of umeclidinium 62.5 mcg compared with tiotropium 18 mcg in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:719\u201330.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"626_CR9","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1183\/09031936.00200212","volume":"42","author":"ED Bateman","year":"2013","unstructured":"Bateman ED, Ferguson GT, Barnes N, Gallagher N, Green Y, Henley M, et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J. 2013;42:1484\u201394.","journal-title":"Eur Respir J"},{"key":"626_CR10","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/S2213-2600(14)70065-7","volume":"2","author":"M Decramer","year":"2014","unstructured":"Decramer M, Anzueto A, Kerwin E, Kaelin T, Richard N, Crater G, et al. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24\u00a0weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. Lancet Respir Med. 2014;2:472\u201386.","journal-title":"Lancet Respir Med"},{"key":"626_CR11","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1016\/j.rmed.2014.10.002","volume":"108","author":"MR Maleki-Yazdi","year":"2014","unstructured":"Maleki-Yazdi MR, Kaelin T, Richard N, Zvarich M, Church A. Efficacy and safety of umeclidinium\/vilanterol 62.5\/25\u00a0mcg and tiotropium 18\u00a0mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial. Respir Med. 2014;108:1752\u201360.","journal-title":"Respir Med"},{"key":"626_CR12","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1183\/09031936.00136014","volume":"45","author":"R Buhl","year":"2015","unstructured":"Buhl R, Maltais F, Abrahams R, Bjermer L, Derom E, Ferguson G, et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2\u20134). Eur Respir J. 2015;45:969\u201379.","journal-title":"Eur Respir J"},{"key":"626_CR13","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.2147\/COPD.S72482","volume":"9","author":"R ZuWallack","year":"2014","unstructured":"ZuWallack R, Allen L, Hernandez G, Ting N, Abrahams R. Efficacy and safety of combining olodaterol Respimat\u00ae and tiotropium HandiHaler\u00ae in patients with COPD: results of two randomized, double-blind, active-controlled studies. Int J Chron Obstruct Pulmon Dis. 2014;9:1133\u201344.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"626_CR14","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1016\/j.rmed.2015.08.002","volume":"109","author":"D Singh","year":"2015","unstructured":"Singh D, Ferguson GT, Bolitschek J, Gronke L, Hallmann C, Bennett N, et al. Tiotropium\u00a0+\u00a0olodaterol shows clinically meaningful improvements in quality of life. Respir Med. 2015;109:1312\u20139.","journal-title":"Respir Med"},{"key":"626_CR15","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/S2213-2600(13)70052-3","volume":"1","author":"JA Wedzicha","year":"2013","unstructured":"Wedzicha JA, Decramer M, Ficker JH, Niewoehner DE, Sandstrom T, Taylor AF, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med. 2013;1:199\u2013209.","journal-title":"Lancet Respir Med"},{"key":"626_CR16","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/j.chest.2016.02.646","volume":"149","author":"L Calzetta","year":"2016","unstructured":"Calzetta L, Rogliani P, Matera MG, Cazzola M. A systematic review with meta-analysis of dual bronchodilation with LAMA\/LABA for the treatment of stable COPD. Chest. 2016;149:1181\u201396.","journal-title":"Chest"},{"key":"626_CR17","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1177\/1753465815624612","volume":"10","author":"M Schlueter","year":"2016","unstructured":"Schlueter M, Gonzalez-Rojas N, Baldwin M, Groenke L, Voss F, Reason T. Comparative efficacy of fixed-dose combinations of long-acting muscarinic antagonists and long-acting \u03b22-agonists: a systematic review and network meta-analysis. Ther Adv Respir Dis. 2016;10:89\u2013104.","journal-title":"Ther Adv Respir Dis"},{"key":"626_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/s41030-017-0048-0","author":"KYJ Sion","year":"2017","unstructured":"Sion KYJ, Huisman EL, Punekar YS, Naya I, Ismaila AS. A network meta-analysis of long-acting muscarinic antagonist (LAMA) and long-acting \u03b22-agonist (LABA) combinations in COPD. Pulm Ther. 2017. doi:\n                    10.1007\/s41030-017-0048-0\n                    \n                  .","journal-title":"Pulm Ther"},{"key":"626_CR19","unstructured":"GlaxoSmithKline. ANORO\u2122 ELLIPTA\u00ae. Highlights of prescribing information. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/203975s000lbl.pdf\n                    \n                  . Accessed 9 May 2017."},{"key":"626_CR20","unstructured":"Boehringer Ingelheim International GmbH. STIOLTO\u2122 RESPIMAT\u00ae. Highlights of prescribing information. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/206756s001lbl.pdf\n                    \n                  . Accessed 9 May 2017."},{"key":"626_CR21","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1183\/09031936.04.00014304","volume":"23","author":"BR Celli","year":"2004","unstructured":"Celli BR, MacNee W, Force AET. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS\/ERS position paper. Eur Respir J. 2004;23:932\u201346.","journal-title":"Eur Respir J"},{"key":"626_CR22","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1164\/ajrccm.159.1.9712108","volume":"159","author":"JL Hankinson","year":"1999","unstructured":"Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general US population. Am J Respir Crit Care Med. 1999;159:179\u201387.","journal-title":"Am J Respir Crit Care Med"},{"key":"626_CR23","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1378\/chest.93.3.580","volume":"93","author":"DA Mahler","year":"1988","unstructured":"Mahler DA, Wells CK. Evaluation of clinical methods for rating dyspnea. Chest. 1988;93:580\u20136.","journal-title":"Chest"},{"key":"626_CR24","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1183\/09031936.00102509","volume":"34","author":"PW Jones","year":"2009","unstructured":"Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD Assessment Test. Eur Respir J. 2009;34:648\u201354.","journal-title":"Eur Respir J"},{"key":"626_CR25","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s12931-014-0124-z","volume":"15","author":"NK Leidy","year":"2014","unstructured":"Leidy NK, Murray LT, Monz BU, Nelsen L, Goldman M, Jones PW, et al. Measuring respiratory symptoms of COPD: performance of the EXACT-respiratory Symptoms Tool (E-RS) in three clinical trials. Respir Res. 2014;15:124.","journal-title":"Respir Res"},{"key":"626_CR26","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1136\/thoraxjnl-2013-204428","volume":"69","author":"NK Leidy","year":"2014","unstructured":"Leidy NK, Sexton CC, Jones PW, Notte SM, Monz BU, Nelsen L, et al. Measuring respiratory symptoms in clinical trials of COPD: reliability and validity of a daily diary. Thorax. 2014;69:443\u20139.","journal-title":"Thorax"},{"key":"626_CR27","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1471-2466-14-4","volume":"14","author":"KR Chapman","year":"2014","unstructured":"Chapman KR, Beeh KM, Beier J, Bateman ED, D\u2019Urzo A, Nutbrown R, et al. A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study. BMC Pulm Med. 2014;14:4.","journal-title":"BMC Pulm Med"},{"key":"626_CR28","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1183\/09031936.00054213","volume":"43","author":"A Agusti","year":"2014","unstructured":"Agusti A, de Teresa L, De Backer W, Zvarich MT, Locantore N, Barnes N, et al. A comparison of the efficacy and safety of once-daily fluticasone furoate\/vilanterol with twice-daily fluticasone propionate\/salmeterol in moderate to very severe COPD. Eur Respir J. 2014;43:763\u201372.","journal-title":"Eur Respir J"},{"key":"626_CR29","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.rmed.2009.11.011","volume":"104","author":"M Ichinose","year":"2010","unstructured":"Ichinose M, Fujimoto T, Fukuchi Y. Tiotropium 5microg via Respimat and 18microg via HandiHaler; efficacy and safety in Japanese COPD patients. Respir Med. 2010;104:228\u201336.","journal-title":"Respir Med"},{"key":"626_CR30","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1081\/COPD-200053377","volume":"2","author":"JF Donohue","year":"2005","unstructured":"Donohue JF. Minimal clinically important differences in COPD lung function. COPD. 2005;2:111\u201324.","journal-title":"COPD"},{"key":"626_CR31","first-page":"381","volume":"11","author":"PM Calverley","year":"2016","unstructured":"Calverley PM, Postma DS, Anzueto AR, Make BJ, Eriksson G, Peterson S, et al. Early response to inhaled bronchodilators and corticosteroids as a predictor of 12-month treatment responder status and COPD exacerbations. Int J Chron Obstruct Pulmon Dis. 2016;11:381\u201390.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"626_CR32","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/1465-9921-12-161","volume":"12","author":"PW Jones","year":"2011","unstructured":"Jones PW, Donohue JF, Nedelman J, Pascoe S, Pinault G, Lassen C. Correlating changes in lung function with patient outcomes in chronic obstructive pulmonary disease: a pooled analysis. Respir Res. 2011;12:161.","journal-title":"Respir Res"},{"key":"626_CR33","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/1465-9921-12-40","volume":"12","author":"M Westwood","year":"2011","unstructured":"Westwood M, Bourbeau J, Jones PW, Cerulli A, Capkun-Niggli G, Worthy G. Relationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review. Respir Res. 2011;12:40.","journal-title":"Respir Res"},{"issue":"3","key":"626_CR34","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.chest.2017.04.174","volume":"152","author":"AD Zider","year":"2017","unstructured":"Zider AD, Wang X, Buhr RG, Sirichana W, Barjaktarevic IZ, Cooper CB. Reduced COPD exacerbation risk correlates with improved FEV1: a meta-regression analysis. Chest. 2017;152(3):494\u2013501.","journal-title":"Chest"},{"key":"626_CR35","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/bcp.12545","volume":"79","author":"D Singh","year":"2015","unstructured":"Singh D. New combination bronchodilators for chronic obstructive pulmonary disease: current evidence and future perspectives. Br J Clin Pharmacol. 2015;79:695\u2013708.","journal-title":"Br J Clin Pharmacol"},{"key":"626_CR36","first-page":"PA304","volume":"48","author":"I Naya","year":"2016","unstructured":"Naya I, Tombs L, Mullerova H, Compton C, Jones P. Long-term outcome following first clinically important deterioration in COPD. Eur Respir J. 2016;48:PA304.","journal-title":"Eur Respir J"},{"key":"626_CR37","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.2147\/COPD.S133307","volume":"12","author":"AR Anzueto","year":"2017","unstructured":"Anzueto AR, Vogelmeier CF, Kostikas K, Mezzi K, Fucile S, Bader G, et al. The effect of indacaterol\/glycopyrronium versus tiotropium or salmeterol\/fluticasone on the prevention of clinically important deterioration in COPD. Int J Chron Obstruct Pulmon Dis. 2017;12:1325\u201337.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"626_CR38","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1007\/s12325-016-0430-6","volume":"33","author":"MR Maleki-Yazdi","year":"2017","unstructured":"Maleki-Yazdi MR, Singh D, Anzueto A, Tombs L, Fahy WA, Naya I. Assessing short-term deterioration in maintenance-naive patients with COPD receiving umeclidinium\/vilanterol and tiotropium: a pooled analysis of three randomized trials. Adv Ther. 2017;33:2188\u201399.","journal-title":"Adv Ther"},{"key":"626_CR39","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.2147\/COPD.S101612","volume":"11","author":"D Singh","year":"2016","unstructured":"Singh D, Maleki-Yazdi MR, Tombs L, Iqbal A, Fahy WA, Naya I. Prevention of clinically important deteriorations in COPD with umeclidinium\/vilanterol. Int J Chron Obstruct Pulmon Dis. 2016;11:1413\u201324.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"626_CR40","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1164\/ajrccm.163.6.2003172","volume":"163","author":"JM Marin","year":"2001","unstructured":"Marin JM, Carrizo SJ, Gascon M, Sanchez A, Gallego B, Celli BR. Inspiratory capacity, dynamic hyperinflation, breathlessness, and exercise performance during the 6-min-walk test in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;163:1395\u20139.","journal-title":"Am J Respir Crit Care Med"},{"key":"626_CR41","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1164\/rccm.200407-855OC","volume":"171","author":"F Pitta","year":"2005","unstructured":"Pitta F, Troosters T, Spruit MA, Probst VS, Decramer M, Gosselink R. Characteristics of physical activities in daily life in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;171:972\u20137.","journal-title":"Am J Respir Crit Care Med"},{"key":"626_CR42","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1177\/1479972315576143","volume":"12","author":"CS Silva","year":"2015","unstructured":"Silva CS, Nogueira FR, Porto EF, Gazzotti MR, Nascimento OA, Camelier A, et al. Dynamic hyperinflation during activities of daily living in COPD patients. Chron Respir Dis. 2015;12:189\u201396.","journal-title":"Chron Respir Dis"},{"key":"626_CR43","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1136\/thoraxjnl-2014-206345","volume":"70","author":"R Buhl","year":"2015","unstructured":"Buhl R, Gessner C, Schuermann W, Foerster K, Sieder C, Hiltl S, et al. Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study. Thorax. 2015;70:311\u20139.","journal-title":"Thorax"},{"key":"626_CR44","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/thoraxjnl-2014-206732","volume":"71","author":"Y Oba","year":"2016","unstructured":"Oba Y, Sarva ST, Dias S. Efficacy and safety of long-acting \u03b2-agonist\/long-acting muscarinic antagonist combinations in COPD: a network meta-analysis. Thorax. 2016;71:15\u201325.","journal-title":"Thorax"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-017-0626-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-017-0626-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-017-0626-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,21]],"date-time":"2019-01-21T14:27:13Z","timestamp":1548080833000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-017-0626-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":44,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["626"],"URL":"https:\/\/doi.org\/10.1007\/s12325-017-0626-4","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"24 August 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2017","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}